Announcement • Jun 05
ADBiotech Co., Ltd. announced that it has received KRW 13.261700256 billion in funding On June 4, 2026, the ADBiotech Co., Ltd. closed the transaction and amended the term of transaction, issued 7,270,669 common shares at an issue price of KRW 1,824 for the proceeds of KRW 13,261,700,256. Transaction involves participation of BK Partners Fund No. 1 for 5,987,774 shares and Ahn Byeong-hwa for 1,282,895 shares. Announcement • May 29
ADBiotech Co., Ltd. announced that it expects to receive KRW 3 billion in funding ADBiotech Co., Ltd. has announced a private placement of Series 10 Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 3,000,000,000 on May 28, 2026. The transaction involves the new investor participation of BK Partners Fund No. 1 for KRW 3,000,000,000. The bonds are 100% convertible into 1,120,238 common shares of the company at a conversion price value of KRW 2,678 and carry interest rate of 0% and maturity interest rate of 3%. The conversion billing period starts from June 5, 2027 to May 5, 2031.The transaction has been approved by the board of directors of the company. The bonds have a maturity date of June 5, 2031. The transaction is expected to close on June 5, 2026. Announcement • Mar 17
ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026 ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea